Report of Expert Consultations on Rapid Molecular Testing to Detect Drug-Resistant Tuberculosis in the United States

( PDF - 157KB)

This report is based on contributions of an expert panel of consultants (E Desmond PhD, California Dept. of Public Health; K Field RN MSN, Washington Dept. of Health; P Griffin BBA, Kansas Dept. of Health and Environment; D Ingman BS MT DPHHS, Montana Dept. of Public Health and Human Services; K Musser PhD, New York State Dept. of Health; M Oxtoby MD, New York State Dept. of Health; V Pruitt, Alabama Dept. of Public Health; J Razeq PhD, Maryland Dept. of Health; M Salfinger MD, Florida Dept. of Health; B Seaworth MD, Heartland National TB Training and Education Center; J Watt MD MPH, California Dept. of Public Health; K Wroblewski MPH, Association of Public Health Laboratories; S Zanto CLS(NCA) SM(NRM), Montana Public Health Laboratory) and CDC participants (K Ijaz MD, B Metchock DrPH, J Posey PhD, A Starks PhD, and T Shinnick PhD, Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention).

Contents

• Executive Summary
• Introduction
• Background on Tests for Molecular Detection of Drug Resistance (DR)
• General Considerations and Principles for a Molecular DR Testing Service
• Possible Scenarios and Scope of Testing for a Molecular DR Testing Service
• Research Needs
• General Recommendations of the Expert Panel
• Communication Plan for the Report
• Recommendations
• References
• Panel Members and CDC Participants
• Appendices
  • Appendix 1: Molecular Basis of Drug Resistance and Molecular DR Tests
  • Appendix 2: Roles and Responsibilities in a Regional Laboratory System for Providing for Molecular DR Testing for TB
  • Appendix 3: Flow Chart of Steps in a Molecular DR Testing Service